Saturday, July 11, 2026

Patent intelligence · US

US 6544549

Multilamellar coalescence vesicles (MLCV) containing biologically active compounds

expired A61KA61K9/1277A61K9/1278
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 308
Patent details — US 6544549
Jurisdiction
US
Status
expired
Grant date
Apr 8, 2003
Expiration
Apr 3, 2023
Applicant
Biomira USA Inc.
Claims
20
CPC classes
A61K, A61K9/1277, A61K9/1278
View on Google Patents ↗

Quick answer

US 6544549 (Multilamellar coalescence vesicles (MLCV) containing biologically active compounds) is held by Biomira USA Inc.. Status: expired. Granted Apr 8, 2003. Expires Apr 3, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Biomira USA Inc.
Grant date
Expiration
Claims
20
CPC classes
A61K, A61K9/1277, A61K9/1278

More from Biomira USA Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 6544549?

US 6544549 (Multilamellar coalescence vesicles (MLCV) containing biologically active compounds) is held by Biomira USA Inc.. Status: expired. Granted Apr 8, 2003. Expires Apr 3, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6544549?

Biomira USA Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 6544549 expire?

Our index shows an expiration date of Apr 3, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.